08:48am Thursday 19 October 2017

WATCHMAN offers patients with atrial fibrillation alternative to warfarin therapy

ANN ARBOR, Mich. – The University of Michigan Frankel Cardiovascular Center is among the first heart centers in the nation to use the WATCHMAN implant to help prevent stroke among patients with non-valvular atrial fibrillation.

Atrial fibrillation is the most common cardiac arrhythmia, resulting in a too fast or irregular heart rhythm among more than 5 million Americans.

Doctors often prescribe the blood-thinning medication warfarin to reduce risk of stroke, but it is not well-tolerated by some patients and has a significant risk for bleeding complications.

WATCHMAN closes off an area of the heart called the left atrial appendage closure where harmful blood clots can form and then enter the bloodstream causing a stroke.  By closing off the LAA, the risk of stroke and other systemic embolization may be reduced and, over time, patients may be able to stop taking warfarin.

“The WATCHMAN device offers patients with non-valvular atrial fibrillation a potentially life-changing stroke risk treatment option which could free them from the challenges of long-term warfarin therapy,” says electrophysiologist and U-M assistant professor of internal medicine Eric D. Good, D.O., who served as principal investigator at the U-M during the major clinical trials leading up to the device’s recent FDA approval.

The device is shaped like a parachute and implanted during a one-time minimally invasive procedure in an electrophysiology lab. WATCHMAN is intended for those whom warfarin therapy is risky.

Danny Morris, 65, is the first U-M patient to receive the commercially released WATCHMAN device. He has been diagnosed with complex heart and kidney issues and has a history of bleeding complications while on long-term warfarin.

During clinical trials involving more than 2,400 patients and nearly 6,000 patient-years follow-up, WATCHMAN provided protection from disabling stroke, hemorragic stroke and cardiovascular death comparable to warfarin.

“This advanced technology provides physicians at the U-M with a breakthrough stroke risk reduction option for patients with this type of atrial fibrillation,” says electrophysiologist Hakan Oral, M.D., professor of internal medicine and Director of the Arrhythmia Program at the University of Michigan. “It allows us to intervene at the source of the majority of stroke-causing blood clots in non-valvular AF.”

The Arrhythmia Program at the University of Michigan is an internationally known referral center for the management of complex arrhythmias. Each year the team of heart specialists performs a high volume of ablations and device procedures and along with the Center for Arrhythmia Research is moving forward the treatment of the most challenging and prevalent heart rhythm conditions.

###

To schedule an appointment to discuss your heart arrhythmia or other cardiovascular condition, call 888-287-1082, or email us at CVCCallCtr@med.umich.edu.  

Media Contact: Shantell Kirkendoll 734-764-2220

Share on:
or:

Health news